On May 19, 2021 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021 (Press release, Vaccinex, MAY 19, 2021, View Source [SID1234580420]). Dr. Zauderer will present updates on Vaccinex’s neurology programs in Huntington’s and Alzheimer’s disease and its collaboration with Merck (Keynote B84) for combination immunotherapy in Head & Neck Squamous Cell Carcinoma with Vaccinex’s pepinemab antibody and Merck’s KEYTRUDA. Management will be available during the conference for virtual one-on-one meetings.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Date: Tuesday, June 1
Time: 4:30pm ET
Following the presentation, a live video webcast may be accessed through the "Events" page of the Vaccinex website, www.vaccinex.com.